🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

43+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 43 recruiting trials for “graft-versus-host-disease

Phase 2RecruitingNCT07124078

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 38 sites📅 Started Mar 2026View details ↗
RecruitingNCT07127926

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

👨‍⚕️ Amin Alousi, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07138196

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

🏥 Qurient Co., Ltd.📍 8 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT07116031

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

🏥 Sanofi📍 23 sites📅 Started Dec 2025View details ↗
NARecruitingNCT07166848

Electrostimulation Study for Ocular Graft vs. Host Disease

👨‍⚕️ Zhonghui Luo, MD, PhD, Massachusetts Eye and Ear Infirmary📍 1 site📅 Started Nov 2025View details ↗
Phase 2RecruitingNCT07246031

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

👨‍⚕️ Xiaodong Mo, PhD, Peking University People's Hospital📍 1 site📅 Started Oct 2025View details ↗
Phase 1RecruitingNCT06233110

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

👨‍⚕️ Chenyu Lin, MD, Duke Health📍 1 site📅 Started Oct 2025View details ↗
NARecruitingNCT07184853

Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

🏥 First Affiliated Hospital of Zhejiang University📍 1 site📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT07118254

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

🏥 Lubris Bio Pty Ltd📍 3 sites📅 Started Sep 2025View details ↗
Phase 4RecruitingNCT06824103

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 19 sites📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT07011810

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

👨‍⚕️ Stephanie J. Lee, MD, MPH, Fred Hutch/University of Washington Cancer Consortium📍 3 sites📅 Started Aug 2025View details ↗
Phase 3RecruitingNCT07047456

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT

👨‍⚕️ Xiaoyu Zhu, Ph.D, The First Affiliated Hospital of USTC📍 1 site📅 Started Jul 2025View details ↗
Phase 1, PHASE2RecruitingNCT07012304

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

🏥 Yujun DONG📍 1 site📅 Started Jun 2025View details ↗
Phase 1, PHASE2RecruitingNCT06843408

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 9 sites📅 Started Jun 2025View details ↗
Phase 2RecruitingNCT06799195

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

👨‍⚕️ Moataz Ellithi, MBChB, University of Nebraska📍 1 site📅 Started Jun 2025View details ↗
Phase 1, PHASE2Enrolling by InvitationNCT07162688

Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.

👨‍⚕️ Ting Yang, MD, PhD, First Affiliated Hospital of Fujian Medical University📍 1 site📅 Started May 2025View details ↗
Phase 2RecruitingNCT06663722

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

👨‍⚕️ Trent P Wang, DO, University of Miami📍 1 site📅 Started May 2025View details ↗
RecruitingNCT07314892

Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).

👨‍⚕️ Jan Puchowski, MD, Department of Hematology and Transplantology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland📍 1 site📅 Started Apr 2025View details ↗
Phase 3RecruitingNCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

👨‍⚕️ Incyte Medical Monitor, Incyte Corporation📍 28 sites📅 Started Apr 2025View details ↗
Phase 3RecruitingNCT06585774

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

👨‍⚕️ Albert Assad, MD, Incyte Corporation📍 115 sites📅 Started Jan 2025View details ↗
Page 1 of 3Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →